SOZEMPA
Live / Registered — Registered (as of 23 May 2023)
What this means for you
Registered since 23 May 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97333970
- Registration number
- 7059516
- Mark type
- Stylized text
- Filed
- 28 Mar 2022
- Published for opposition
- 07 Mar 2023
- Registered
- 23 May 2023
- Attorney of record
- Karl M. Zielaznicki, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for use in the field of neuroscience, namely, for the treatment of neurological and nervous system diseases and disorders; pharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome
Owner
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon, CH
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon, CH
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon, CH
Prosecution history
- 23 May 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 23 May 2023 — REGISTERED-PRINCIPAL REGISTER
- 07 Mar 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 Mar 2023 — PUBLISHED FOR OPPOSITION
- 15 Feb 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Jan 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Jan 2023 — EXAMINER'S AMENDMENT ENTERED
- 31 Jan 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 31 Jan 2023 — EXAMINERS AMENDMENT E-MAILED
- 31 Jan 2023 — EXAMINERS AMENDMENT -WRITTEN
- 14 Jan 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 13 Jan 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 13 Jan 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 27 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 27 Sept 2022 — NON-FINAL ACTION E-MAILED